- Adherence to molecular testing recommendations.
| Molecular testing | n (%) |
|---|---|
| EGFR | |
| The candidates for this test are stage IV and non-squamous NSCLC (n=30) | 30 (100) |
| ALK | |
| For the cases who are stage IV and non-squamous NSCLC and wild EGFR (n=23) | 19 (82.6) |
| ROS1 | |
| For the cases who are stage IV and non-squamous NSCLC and wild EGFR and ALK (n=21) | 15 (71.4) |
| PD-L1 | |
| For stage IV (n=42) | 25 (59.5) |
ALK: anaplastic lymphoma kinase, EGFR: epidermal growth factor receptor, ROS1: c-ros oncogene 1, PD-L1: programmed death ligand 1